Actively Recruiting

FEMALE
NCT07196033

Asian Gynecological Brachytherapy Registry in Cervical Cancer

Led by Tata Memorial Hospital · Updated on 2026-02-09

1000

Participants Needed

5

Research Sites

117 weeks

Total Duration

On this page

Sponsors

T

Tata Memorial Hospital

Lead Sponsor

C

Chiang Mai University, Thailand

Collaborating Sponsor

AI-Summary

What this Trial Is About

Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,000 deaths annually, with over 85% occurring in low- and middle-income nations, primarily in Asia. Factors contributing to this burden include limited access to preventive care, inadequate screening, high rates of human papillomavirus infection, and cultural barriers that delay medical attention. For patients with advanced cervical cancer, the standard treatment involves external beam radiation therapy along with chemotherapy followed by internal radiation, known as Brachytherapy. This technique uses unique set of devices placed internally at the tumor sitegiving localized radiation to the residual tumor tissue. While advanced brachytherapy techniques have been developed and practiced in Europe and American countries yielding excellent clinical outcomes, there is insufficient data on the use and results of such advanced brachytherapy techniques in Asian populations, leading to a lack of standardized practices. To address these issues, the Asian Gynecological Brachytherapy Registry (ABGR) has been established as a collaborative platform for data collection and analysis on the use of Brachytherapy techniques. This registry aims to consolidate information from various healthcare settings across Asia, enhancing understanding of cervical cancer's epidemiology, evaluating treatment effectiveness, and identifying areas for improvement in patient care.

CONDITIONS

Official Title

Asian Gynecological Brachytherapy Registry in Cervical Cancer

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype.
  • Planned for treatment with definitive chemo-radiation and brachytherapy using X-ray, CT, CT-Ultrasound, or MRI based planning.
Not Eligible

You will not qualify if you...

  • Neuroendocrine cancer of the cervix or other rare histology subtypes.
  • Patients with metastatic cervical cancer not planned for radical doses of pelvic radiation therapy or brachytherapy.
  • Patients undergoing postoperative radiation therapy or radiation therapy for recurrent disease.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Tata Memorial Center

Mumbai, Maharashtra, India, 400012

Actively Recruiting

2

Gunma University

Maebashi, Japan, Japan

Not Yet Recruiting

3

Juntendo University

Tokyo, Japan, Japan

Not Yet Recruiting

4

Mahidol University

Bangkok, Thailand, Thailand

Not Yet Recruiting

5

Chiang Mai University

Chiang Mai, Thailand, Thailand

Not Yet Recruiting

Loading map...

Research Team

D

Dr. Supriya Chopra

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here